• China’s NMPA cleared the NDA for CARDAMYST (etripamil) nasal spray to convert acute PSVT episodes to sinus rhythm in adults.
• Approval backed by Phase III RAPID data: 64% converted within 30 minutes vs 31% on placebo.
• China Phase III JX02002 also met its primary endpoint, supporting commercialization of an at-home, self-administered acute PSVT therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12319426), on September 03, 2026, and is solely responsible for the information contained therein.